000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (clinicaltrials.gov) - Aug 2, 2025 - P1/2 | N=96 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2029 ➔ Aug 2032 | Trial primary completion date: Aug 2025 ➔ Aug 2028
Trial completion date • Trial primary completion date • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor • IDH1 • IDH2
|